Chimeric Therapeutics (ASX: CHM) managing director and chief executive office Jennifer Chow joins Small Caps to discuss the latest news in the development of its CAR-T therapy CHM 2101.

Ms Chow says the cell therapy company received positive feedback from a pre-investigational new drug (pre-IND) meeting with the US Food and Drug Administration (FDA) in the lead up to a phase 1A study of the drug in treating gastrointestinal and neuroendocrine tumours.

The FDA’s responses provide a clear path to an IND submission for CHM 2101. Chimeric is also evaluating another novel CAR-T therapy, CHM 1101, to treat recurrent or progressive glioblastoma (brain cancer).

Articles:
https://smallcaps.com.au/chimeric-therapeutics-reveals-positive-pre-ind-us-fda-chm-2101/
https://smallcaps.com.au/chimeric-therapeutics-doses-final-cohort-brain-cancer-clinical-trial-advances-chm-2101-candidate/

For more information on Chimeric Therapeutics:
https://smallcaps.com.au/stocks/CHM/

See omnystudio.com/listener for privacy information.